Vida Ventures III, L.P.

Vida Ventures III, L.P. is the third flagship fund raised by Vida Ventures, a Boston-based biomedical venture capital firm exclusively dedicated to transforming breakthrough scientific discoveries into life-changing therapies for patients with difficult-to-treat diseases. Closed in June 2021 with $825 million in capital commitments, Vida III represents a meaningful step-up from the firm's earlier vehicles and reflects growing institutional conviction in the large-unmet-medical-need, precision-medicine investment thesis that Vida has executed since its founding. Among the largest life sciences venture funds closed that year, Vida III underscores the firm's ability to attract global institutional capital to a focused therapeutic-area strategy in the most capital-intensive segment of innovation-stage biotechnology.

Vida Ventures III invests primarily in early-to-growth-stage biomedical companies developing novel therapeutics across oncology — including precision oncology, radioligand therapeutics, and cancer immunotherapy — immunology and inflammatory diseases, neuroscience and neurological disorders, protein therapeutics, and genetic medicines. The fund targets companies in the United States, Canada, and Europe whose programs are built on compelling drug targets, differentiated mechanisms of action, and credible regulatory pathways to approval. Vida's investment approach combines rigorous scientific diligence with hands-on operational engagement, providing portfolio companies access to clinical development expertise, manufacturing partnerships, and an extensive network of pharmaceutical executives who support companies from early preclinical stages through clinical proof-of-concept and exit milestones.

Since inception, Vida Ventures has deployed capital across more than 30 portfolio companies spanning oncology, autoimmunity, rare genetic diseases, and neurology, building a track record of high-value licensing transactions and clinical development partnerships with major pharmaceutical companies. The firm's scientific advisory network includes leading academic investigators and key opinion leaders across multiple therapeutic areas, providing differentiated diligence capabilities that complement the team's own deep biomedical expertise. Vida III continues to invest in companies developing transformative medicines for diseases where current treatment options remain inadequate, with particular emphasis on molecularly defined patient populations and next-generation modalities including cell therapies, gene therapies, and advanced protein biologics.